KRAS and neoplasm: To evaluate the combined diagnostic performance and prognostic value of liquid biopsy and circulating biomarkers (CTCs. KRAS mutant alleles and tumor-specific exosomes) to identify ideal candidates for upfront surgery in resectable PDAC patients using four different assay platforms.